Altered pharmacokinetics of paclitaxel by the concomitant use of morin in rats

International Journal of Pharmaceutics

Volumn 323, Issue 1-2, 2006, Pages 81-85

  Choi, Byung Chul ^a   Choi, Jun Shik ^b   Han, Hyo Kyung ^b  

^a Chung Ang University   (South Korea)

^b Chosun University   (South Korea)

Author keywords

Bioavailability; Morin; Paclitaxel; Pharmacokinetics; Rats

Indexed keywords

MORIN; PACLITAXEL;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EXPOSURE; DRUG HALF LIFE; DRUG INHIBITION; DRUG ISOLATION; GASTROINTESTINAL TRACT; INTESTINE ABSORPTION; MALE; NONHUMAN; PLASMA HALF LIFE; PRIORITY JOURNAL; RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTIOXIDANTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DRUG INTERACTIONS; FLAVONOIDS; INJECTIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; P-GLYCOPROTEIN; PACLITAXEL; RATS; RATS, SPRAGUE-DAWLEY;

EID: 33748684356     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2006.05.046     Document Type: Article

References (34)

1. Berg S.L., Tolcher A., O'Shaughnessy J.A., Denicoff A.M., Noone M., Ognibene F.P., Cowan K.H., and Balis F.M. Effect of R-verapamil on the pharmacokinetics of paclitaxel in women with breast cancer. J. Clin. Oncol. 13 (1995) 2039-2042
2. Choi J.S., and Han H.K. Enhanced oral exposure of diltiazem by the concomitant use of naringin in rats. Int. J. Pharm. 305 (2005) 122-128
3. Choi S.U., Lee B.H., Kim K.H., Choi E.J., Park S.H., Shin H.S., Yoo S.E., Jung N.P., and Lee C.O. Novel multidrug-resistance modulators, KR-30026 and KR-30031, in cancer cells. Anticancer Res. 17 (1997) 4577-4582
4. Critchfield J.W., Welsh C.J., Phang J.M., and Yeh G.C. Modulation of adriamycin accumulation and efflux by flavonoids in HCT-15 colon cells. Activation of P-glycoprotein as a putative mechanism. Biochem. Pharmacol. 48 (1994) 1437-1445
5. Crosasso P., Ceruti M., Brusa P., Arpicco S., and Cattel L. Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes. J. Control. Release 63 (2000) 19-30
6. Dixon R.A., and Steele C.L. Flavonoids andisoflavonoids-a gold mine for metabolic engineering. Trends Plant Sci. 4 (1999) 394-400
7. Dupuy J., Larrieu G., Sutra J.F., Lespine A., and Alvinerie M. Enhancement of moxidectin bioavailability in lamb by a natural flavonoid: quercetin. Vet. Parasitol. 112 (2003) 337-347
8. Eagling V.A., Profit L., and Back D.J. Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. Br. J. Clin. Pharmacol. 48 (1999) 543-552
9. Fang S.H., Hou Y.C., Chang W.C., Hsiu S.L., Chao P.D., and Chiang B.L. Morin sulfates/glucuronides exert anti-inflammatory activity on activated macrophages and decreased the incidence of septic shock. Life Sci. 74 (2003) 743-756
10. Fisher G.A., and Sikic B.I. Clinical studies with modulators of multidrug resistance. Hematol. Oncol. Clin. North Am. 9 (1995) 363-382
11. Francis A.R., Shetty T.K., and Bhattacharya R.K. Modulating effect of plant flavonoids on the mutagenicity of N-methyl-N′-nitro-N-nitrosoguanidine. Carcinogenesis 10 (1989) 1953-1955
12. Gao P., Rush B.D., Pfund W.P., Huang T., Bauer J.M., Morozowich W., Kuo M.S., and Hageman M.J. Development of a supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability. J. Pharm. Sci. 92 (2003) 2386-2398
13. Gottesman M.M., and Pastan I. Clinical trials of agents that reverse multidrug-resistance. J. Clin. Oncol. 7 (1989) 409-411
14. Hanasaki Y., Ogawa S., and Fukui S. The correlation between active oxygens scavenging and antioxidative effects of flavonoids. Free Radic. Biol. Med. 16 (1994) 845-850
15. Hodek P., Trefil P., and Stiborova M. Flavonoids-potent and versaltile biologically active compounds interacting with cytochromes P450. Chem. Biol. Interact. 139 (2002) 1-21
16. Kimura Y., Aoki J., Kohno M., Ooka H., Tsuruo T., and Nakanishi O. P-glycoprotein inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel. Cancer Chemother. Pharmacol. 49 (2002) 322-328
17. Lee S.H., Yoo S.D., and Lee K.H. Rapid and sensitive determination of paclitaxel in mouse plasma by high-performance liquid chromatography. J. Chomatogr. B: Biomed. Sci. Appl. 724 (1999) 357-363
18. Lundberg B.B. A submicron lipid emulsion coated with amphipathic polyethylene glycol for parenteral administration of paclitaxel (Taxol). J. Pharm. Pharmacol. 49 (1997) 16-21
19. Meerum Terwogt J.M., Malingre M.M., Beijnen J.H., ten Bokkel Huinink W.W., Rosing H., Koopman F.J., van Tellingen O., Swart M., and Schellens J.H. Coadministration of oral cyclosporin A enables oral therapy with paclitaxel. Clin. Cancer Res. 5 (1999) 3379-3384
20. Onyuksel H.A., Ramakrishnan S., Chai H.B., and Pezzuto J.M. A mixed micellar formulation suitable for the parenteral administration of taxol. Pharm. Res. 11 (1994) 206-212
21. Ozols R.F., Cunnion R.E., Klecker R.W., Hamilton T.C., Ostchega Y., Parrillo J.E., and Young R.C. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J. Clin. Oncol. 5 (1987) 641-647
22. Panchagnula R. Pharmaceutical aspects of paclitaxel. Int. J. Pharm. 172 (1998) 1-15
23. Rai A., Rajeshkumar N.V., Shord S., and Gulati A. ET(B) receptor agonist, IRL 1620, does not affect paclitaxel plasma pharmacokinetics in breast tumour bearing rats. J. Pharm. Pharmacol. 57 (2005) 869-876
24. Rowinsky E., Eisenhauer E., Chaudhy V., Aqbuck S.G., and Donehower R.C. Clinical toxicities encountered with paclitaxel (TaxolR). Sem. Oncol. 20 (1993) 1-15
25. Salama N.N., Scott K.R., and Eddington N.D. The influence of enaminones on the transport and oral bioavailability of P-glycoprotein substrate therapeutic agents. Int. J. Pharm. 273 (2004) 135-147
26. Scambia G., Ranellett F.O., Panici P.B., Vincenzo D.R., Bonanno G., Frrandina G., Piantelli M., Bussa S., Rumi C., and Ciantriglia M. Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target. Cancer Chemother. Pharmacol. 36 (1994) 448-450
27. Sparreboom A., van Asperen J., Mayer U., Schinkel A.H., Smit J.W., Meijer D.K., Borst P., Nooijen W.J., Bejinen J.W., and van Tellingen O. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. U.S.A. 4 (1997) 2031-2035
28. Vaclavikova R., Horsky S., Simek P., and Gut I. Paclitaxel metabolism in rat and human liver microsomes is inhibited by phenolic antioxidants. Naunyn Schmiedebergs Arch. Pharmacol. 368 (2003) 200-209
29. van Asperen J., van Tellingen O., van der Valk M.A., Rozenhart M., and Beijnen J.H. Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A. Clin. Cancer Res. 4 (1998) 2293-2297
30. Varma M.V., and Panchagnula R. Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo. Eur. J. Pharm. Sci. 25 (2005) 445-453
31. Wang Y.M., Sato H., Adachi I., and Horikoshi I. Preparation and characterization of poly(lactic-co-glycolic acid) microspheres for targeted delivery of novel anticancer agent, taxol. Chem. Pharm. Bull. 44 (1996) 1935-1940
32. Wani M.C., Taylor H.L., Wall M.E., Coggon P., and McPhail A.T. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc. 93 (1971) 2325-2327
33. Woo J.S., Lee C.H., Shim C.K., and Hwang S.J. Enhanced oral bioavailability of paclitaxel by coadministration of the P-glycoprotein inhibitor KR30031. Pharm. Res. 20 (2003) 24-30
34. Zhang S., and Morris M.E. Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J. Pharmacol. Exp. Ther. 304 (2003) 1258-1267